Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why

Impact · against what's priced in

Puma Biotechnology (PBYI) shows positive momentum following a Q1 beat and an upward revision to its 2026 revenue guidance. The news reflects strengthening demand for Nerlynx, providing a fundamental catalyst for the stock's recent rally.

PBYI+0.60

No priced-in read yet

In context

First-quarter Nerlynx sales of $42 million beat the guided $36-$39 million range, leading management to raise total 2026 revenue guidance to $222-$229 million from $214-$221 million.

Read from the article alone

• healthcare
• biotech
• PBYI
• breast cancer
• pharma
• revenue guidance
• sales growth

Search tags